AnaptysBio, Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging +0.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-1.34 | not reported | not reported | |
| Q1 FY26 | not reported | $-1.84 | not reported | not reported | |
| Q4 FY25 | $0.89 | $1.58 | +77.5% | Beat | |
| Q3 FY25 | not reported | $0.52 | not reported | not reported | |
| Q2 FY25 | $-1.50 | $-1.34 | +10.7% | Beat | |
| Q1 FY25 | $-1.30 | $-1.28 | +1.5% | Beat | |
| Q4 FY24 | $-1.61 | $-0.72 | +55.3% | Beat | |
| Q3 FY24 | $-1.72 | $-1.14 | +33.7% | Beat | |
| Q2 FY24 | $-1.20 | $-1.71 | -42.5% | Miss | |
| Q1 FY24 | $-1.54 | $-1.64 | -6.5% | Miss | |
| Q4 FY23 | $-1.74 | $-1.59 | +8.6% | Beat | |
| Q3 FY23 | $-1.72 | $-1.41 | +18.0% | Beat |
Back to ANAB overview · ANAB holders · ANAB KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.